Rituximab in Treating Patients With Refractory or Relapsed Primary CNS Lymphoma

Part of paid clinical trials in Birmingham, Alabama.

Sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Study ID
NCT00072449
Phase
PHASE2
Status
Terminated

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

RATIONALE: Monoclonal antibodies, such as rituximab, can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells. PURPOSE: Phase II trial to study the effectiveness of rituximab in treating patients who have refractory or relapsed primary CNS lymphoma.

Key Dates

Start date
May 31, 2004
Status verified
Jun 2013
Primary completion
Mar 31, 2009
Completion
Jun 30, 2010

Study Design

Enrollment
12 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Rituximab monotherapy
    Rituximab administered at a dose of 375mg/m2 as a single IV infusion every week for up to 8 weeks

Primary Outcome Measure

Radiographic Response [ Time Frame: 1 month, 2 months and then q3months ]

Locations (9)

Find similar trials in Birmingham, AL

Related Studies